Penicillin Drug Market Size
| Study Period | 2019-2029 |
| Market Size (2024) | USD 10.71 Billion |
| Market Size (2029) | USD 12.55 Billion |
| CAGR (2024 - 2029) | 3.21 % |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
Major Players
*Disclaimer: Major Players sorted in no particular order |
Penicillin Drug Market Analysis
The Penicillin Drug Market size is estimated at USD 10.71 billion in 2024, and is expected to reach USD 12.55 billion by 2029, growing at a CAGR of 3.21% during the forecast period (2024-2029).
The initial phase of the COVID-19 outbreak had an adverse impact on the market for antibiotic drugs due to the temporary shutdown of production facilities, export restrictions, disruptions in the supply of goods, and interruptions in services for treatment. However, due to the comprehensive research activities of Penicillin derivatives in inhibiting the SARS-CoV-2 main protease, it is expected to impact the market significantly. For instance, as per the study report published by the Journal of Medicinal Chemistry in May 2022, β-lactams have considerable potential as SARS-CoV-2 main protease inhibitors, which was expected to gain significant results for COVID-19 over the coming years and are likely to achieve market growth.
Some of the major factors fueling growth in the market are the increasing burden of infectious diseases, growing research and development activities in the pharmaceutical industry, and rising demand and development of generic drugs. The rising prevalence of bacterial infections such as pneumonia, respiratory tract infections, scarlet fever, ear, skin, gum, mouth, throat infections, and syphilis, coupled with the need for effective and newer antibiotics, is driving the demand for advanced antibiotics. For instance, according to the data published by the Government of the United Kingdom in March 2023, it has been observed that 52,183 cases of scarlet fever were reported in England between 12 September 2022 to 26 March 2023. Additionally, according to the statistics published by the Minnesota Department of Health, in June 2022, congenital syphilis (CS) increased by 115%, up to 15 cases, in Minnesota in 2021. In addition, as per the same source, there was a 33% increase in syphilis cases, with 1,457 cases in 2021 compared with the previous year, which represented the largest percentage increase. Thus, the rising burden of infectious diseases among the population increases the demand for effective antibiotic treatment options, which is anticipated to increase the demand for penicillin, thereby fuelling market growth.
Furthermore, the rising investments in the manufacturing of essential antibiotics like penicillins likely increase the availability of these products, which is expected to boost market growth. For instance, in November 2022, Sandoz released an additional investment of USD 54.6 million (EUR 50 million) to support increased European manufacturing capacity for finished dosage form (FDF) penicillins. This investment will increase the production of amoxicillin FDFs and other important penicillin compounds.
Thus, all factors above, like the increased burden of infectious diseases and new investments for expanding the manufacturing capacity of penicillin products, likely boost the market growth over the forecast period. However, the increasing resistance to anti-microbials, availability of novel antibacterials, and stringent regulatory frameworks will likely restrain the market growth over the forecast period.
Penicillin Drug Market Trends
Broad Spectrum Segment Expects to Register a Highest CAGR in the Market Over the Forecast Period
Broad-spectrum penicillins work against a variety of disease-causing bacteria as well as the two leading bacterial types, gram-positive and gram-negative bacteria. The broad-spectrum penicillin segment is anticipated to hold a significant share of revenue in the spectrum of activity segment over the forecast period owing to factors such as the rising burden of Gram-positive and Gram-negative bacterial infections, which include pneumonia, urinary tract infections, and gonorrhea, and also with emerging new antibiotics drugs in the market. In addition, when treating Pseudomonas aeruginosa infections, broad-spectrum penicillins frequently combine with aminoglycosides due to their synergistic effects. Hence, the combination of broad-spectrum penicillins with other classes of drugs likely increases the demand for the products in the segment, thereby propelling the market growth in the study period.
The high burden of infectious diseases is anticipated to drive the market growth of broad-spectrum penicillin. For instance, according to the report by WHO in February 2023, the highest burden of meningitis is seen in a region of sub-Saharan Africa, known as the African Meningitis Belt, which is primarily recognized to be at increased risk of meningococcal but also pneumococcal meningitis epidemics. In addition, as per the same source, from 1 November 2022 to 27 January 2023, 559 cases of meningitis, including 18 deaths, were reported from the Zinder Region, southeast of Niger, West Africa. Similarly, the review article published by Microbiology Insights in November 2021 stated that the prevalence of Meningococcal meningitis in epidemic and endemic conditions was 12.1% and 0.76%. This shows the high burden of bacterial meningitis that increases the demand for broad-spectrum penicillins, thereby propelling the market's growth through this segment.
Furthermore, the rising company's focus on research and development activities to address the need for a new class of antibiotics to treat emerging resistant bacteria and related infections also contributes to the market's growth. For instance, in April 2022, Qpex Biopharma, Inc. presented new phase 1 clinical data for their β-lactamase inhibitor xeruborbactam (formerly QPX7728) that is co-administered with beta-lactam antimicrobials which are expected to have new broad-spectrum penicillin combinations that drive the market to grow over the forecast period. Therefore, the studied segment is expected to grow significantly over the forecast period due to the factors above.
North America is Expected to have Significant Share in the Market Over the Forecast Period
North America is expected to hold a significant share of the overall market over the forecast period owing to factors such as the rising prevalence of infectious diseases, the presence of better healthcare infrastructure along with key market players, and increasing awareness programs. Additionally, the growing elderly and pediatric populations in the area, more vulnerable to contracting infectious diseases because of low immunity, are anticipated to support the market's growth.
For instance, according to the National Foundation for Infectious Diseases, updated in March 2022, pneumococcal pneumonia causes an estimated 150,000 hospitalizations annually in the United States. Similarly, as per the report published by the Public Health Agency of Canada in December 2022, in Canada, 11,268 cases of infectious syphilis were reported in 2021 for a rate of 30 per 100,000 population, which was an increase of 20% compared with the previous year's. This illustrates the rise in bacterial infections in the region, which increases the demand for antibiotics like penicillin and likely contributes to the market's growth.
Moreover, the rising company's focus on producing antibiotics like penicillin for treating various infectious diseases is also contributing to the market's growth. For instance, in November 2021, US Antibiotics relaunched the production of the amoxicillin manufacturing facility. This is to boost the production of Amoxicillin products to meet the nation's demand for essential medications. Thus, the market is projected to grow over the forecast period due to the developments above and the increasing burden of infectious diseases in the region.
Penicillin Drug Industry Overview
The penicillin drugs market is competitive, with the presence of several players throughout the world. With the increase in research and development activity, many regional players are expected to contribute to the penicillin drug market over the forecast period. Some of the key players in the market are Pfizer, Inc., Novartis AG, Lupin Limited, GSK plc, and others.
Penicillin Drug Market Leaders
-
Pfizer Inc.
-
Novartis AG
-
GSK plc
-
Lupin Limited
-
Sanofi SA
*Disclaimer: Major Players sorted in no particular order
Penicillin Drug Market News
- April 2023: Baxter International Inc. launched Zosyn (piperacillin and tazobactam) Injection in the United States. Zosyn premix is indicated for the treatment of multiple infections caused by susceptible bacteria and is available in Baxter’s proprietary single-dose Galaxy containers.
- January 2023: Juno Pharmaceuticals Canada received approval from Health Canada to import Amoxicillin powder for oral suspension pursuant to Health Canada’s exceptional importation and sale guidelines.
Penicillin Drug Market Report - Table of Contents
1. INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Burden of Infectious Diseases
4.2.2 Increasing Research and Development Activities in the Pharmaceutical Industry
4.2.3 Increasing Demand and Development of Generic Drugs
4.3 Market Restraints
4.3.1 Antimicrobial Resistance and Availability of Novel Antibacterials
4.3.2 Stringent Regulatory Framework
4.4 Porter's Five Forces Analysis
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Threat of New Entrants
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION (Market Size by Value in USD)
5.1 By Source
5.1.1 Natural
5.1.2 Semisynthetic & Biosynthesis
5.1.2.1 Aminopenicillin
5.1.2.2 Antipseudomonal Penicillin
5.1.2.3 Beta-lactamase Inhibitor
5.1.2.4 Penicillinase-resistant Penicillin
5.2 By Route of Administration
5.2.1 Oral
5.2.2 Parenteral
5.3 By Spectrum of Activity
5.3.1 Narrow Spectrum
5.3.2 Broad Spectrum
5.3.3 Extended Spectrum
5.4 By Distribution Channel
5.4.1 Hospital Pharmacies
5.4.2 Retail Pharmacies
5.4.3 Online Pharmacies
5.4.4 Other Distribution Channels
5.5 Geography
5.5.1 North America
5.5.1.1 United States
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Germany
5.5.2.2 United Kingdom
5.5.2.3 France
5.5.2.4 Italy
5.5.2.5 Spain
5.5.2.6 Rest of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 Australia
5.5.3.5 South Korea
5.5.3.6 Rest of Asia-Pacific
5.5.4 Middle East and Africa
5.5.4.1 GCC
5.5.4.2 South Africa
5.5.4.3 Rest of Middle East and Africa
5.5.5 South America
5.5.5.1 Brazil
5.5.5.2 Argentina
5.5.5.3 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Pfizer, Inc.
6.1.2 Novartis AG
6.1.3 Sanofi SA.
6.1.4 Aenova Group
6.1.5 GSK plc
6.1.6 Merck & Co., Inc.
6.1.7 Teva Pharmaceuticals
6.1.8 Sun Pharmaceutical Industries
6.1.9 Lupin Limited
6.1.10 Cipla Limited
6.1.11 F. Hoffmann-La Roche AG
6.1.12 Wellona Pharma
6.1.13 AdvaCare Pharma
- *List Not Exhaustive
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
Penicillin Drug Industry Segmentation
As per the scope of the report, penicillin refers to a class of antibiotics used as a drug to treat and prevent bacterial infections and diseases. Penicillin is active against several types of bacteria including Streptococcus pneumonia, Listeria, Neisseria gonorrhea, Clostridium, Peptococcus, and Peptostreptococcus. The majority of penicillins used in therapeutics are chemically synthesized from penicillins that are produced naturally.
The penicillin drug market is segmented by source (natural, semisynthetic, and biosynthesis (aminopenicillin, antipseudomonal penicillin, beta-lactamase inhibitor, and penicillinase-resistant penicillin), route of administration (oral and parenteral), spectrum of activity (narrow spectrum, broad spectrum, and extended spectrum), distribution channel (hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels), and geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The market report also covers the estimated market sizes and trends for 17 different countries across major regions globally.
The report offers the value (in USD) for the above segments.
| By Source | ||||||
| Natural | ||||||
|
| By Route of Administration | |
| Oral | |
| Parenteral |
| By Spectrum of Activity | |
| Narrow Spectrum | |
| Broad Spectrum | |
| Extended Spectrum |
| By Distribution Channel | |
| Hospital Pharmacies | |
| Retail Pharmacies | |
| Online Pharmacies | |
| Other Distribution Channels |
| Geography | ||||||||
| ||||||||
| ||||||||
| ||||||||
| ||||||||
|
Penicillin Drug Market Research FAQs
How big is the Penicillin Drug Market?
The Penicillin Drug Market size is expected to reach USD 10.71 billion in 2024 and grow at a CAGR of 3.21% to reach USD 12.55 billion by 2029.
What is the current Penicillin Drug Market size?
In 2024, the Penicillin Drug Market size is expected to reach USD 10.71 billion.
Who are the key players in Penicillin Drug Market?
Pfizer Inc., Novartis AG, GSK plc, Lupin Limited and Sanofi SA are the major companies operating in the Penicillin Drug Market.
Which is the fastest growing region in Penicillin Drug Market?
Asia-Pacific is estimated to grow at the highest CAGR over the forecast period (2024-2029).
Which region has the biggest share in Penicillin Drug Market?
In 2024, the North America accounts for the largest market share in Penicillin Drug Market.
What years does this Penicillin Drug Market cover, and what was the market size in 2023?
In 2023, the Penicillin Drug Market size was estimated at USD 10.37 billion. The report covers the Penicillin Drug Market historical market size for years: 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Penicillin Drug Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029.
Penicillin Drug Industry Report
The Penicillin Drug Market Report offers a comprehensive industry analysis segmented by various factors such as source, class, route of administration, spectrum of activity, distribution channel, and geography. This industry report provides valuable insights into market share, market size, and market growth across different regions including North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report includes a market forecast outlook, providing a detailed market overview and market analysis for the coming years.
The market segmentation covers different sources of penicillin, including natural, biosynthesis, and semisynthesis. Additionally, it examines various classes such as aminopenicillin, antipseudomonal penicillin, beta-lactamase inhibitor, and penicillinase-resistant penicillin. The report also highlights the route of administration, distinguishing between oral and parenteral methods, and details the spectrum of activity, including narrow, broad, intermediate, and extended spectrum.
Distribution channels are analyzed, focusing on hospital pharmacies, retail pharmacies, online pharmacies, and other distribution channels. The report provides industry statistics and industry trends, offering a detailed market review and market outlook. The market data includes market value and market predictions, helping stakeholders understand the market dynamics and identify market leaders.
This industry research is supported by a report example and is available as a report PDF for further reference. The market growth rate and industry sales are discussed, providing insights into the industry's future trajectory. The report also includes industry information and industry reports, ensuring a thorough understanding of the market landscape.
Overall, this report is an essential resource for research companies and stakeholders looking to gain a deeper understanding of the penicillin drug market.
